Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.

MLA

El-Adl, Khaled, et al. “Design, Synthesis, Docking, ADMET Profile, and Anticancer Evaluations of Novel Thiazolidine-2,4-Dione Derivatives as VEGFR-2 Inhibitors.” Archiv Der Pharmazie, vol. 354, no. 7, July 2021, p. e2000491. EBSCOhost, https://doi.org/10.1002/ardp.202000491.

APA

El-Adl, K., Sakr, H., El-Hddad, S. S. A., El-Helby, A.-G. A., Nasser, M., & Abulkhair, H. S. (2021). Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. Archiv Der Pharmazie, 354(7), e2000491. https://doi.org/10.1002/ardp.202000491

Chicago

El-Adl, Khaled, Helmy Sakr, Sanadelaslam S A El-Hddad, Abdel-Ghany A El-Helby, Mohamed Nasser, and Hamada S Abulkhair. 2021. “Design, Synthesis, Docking, ADMET Profile, and Anticancer Evaluations of Novel Thiazolidine-2,4-Dione Derivatives as VEGFR-2 Inhibitors.” Archiv Der Pharmazie 354 (7): e2000491. doi:10.1002/ardp.202000491.